跳至主要内容
临床试验/NCT02657980
NCT02657980已完成3 期

The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder

Ybrain Inc.2 个研究点 分布在 2 个国家目标入组 96 人开始时间: 2015年4月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Ybrain Inc.
入组人数
96
试验地点
2
主要终点
Change in depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)

研究概览

简要总结

Study Type: Interventional Study Design: Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment

详细描述

Patients will be randomized to receive either real or sham-tDCS as well as anti-depressant drugs. tDCS will be applied over the left (anode) and right (cathode) dorsolateral prefrontal cortex (DLPFC). Patients will visit the hospital to get tDCS administrations 5 days a week for 2 weeks. They will be evaluated every 2 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Has a diagnosis of a major depressive disorder as confirmed by the SCID-IV and MINI (without psychotic features)
  • Greater than 22 points of Montgomery-Asberg Depression Rating Scale
  • Aged 19 to
  • Has provided informed consent

排除标准

  • Has other mental disorders diagnosed by Axis-I, except major depressive disorder (However, subject who is diagnosed as both major depressive disorder as well as anxiety disorder can participate the study.)
  • History of suicidal attempt in the last 6 months
  • Diagnosed with bipolar or psychotic major depressive disorder
  • Diagnosed with other depressive disorders: dysthymic disorder, and depressive disorders that are not elsewhere classified.
  • Has hypersensitivity to sertraline ingredients
  • A score of 5 or greater for the question #10 in MADRS
  • Diagnosed with closed angle glaucoma or has a history of glaucoma.
  • History of participation in other clinical trials within 30days.
  • A major and/or unstable medical or neurologic illness
  • Currently taking substances that contain sertraline, mono amine oxidase inhibitor, or pimozide
  • Pregnant or has a positive pregnancy serum test.

结局指标

主要结局

Change in depressive symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)

时间窗: from baseline to Week 6

Measured by Montgomery-Åsberg Depression Rating Scale (MADRS)

次要结局

  • Effect of tDCS on questionnaire results as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)(At 6 weeks after treatment)
  • Effect of tDCS on Depressive Symptoms as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)(At 6 weeks after treatment.)
  • Average change in results for 2, 4, 6 weeks after treatment as assessed by Korean-Beck Anxiety Depression Inventory (K-BAI)(At 2 weeks, 4 weeks and 6 weeks after treatment)
  • Average change in results for 2, 4, 6 weeks after treatment as assessed by Korean-Beck Depression Inventory-II (K-BDI-II)(At 2 weeks, 4 weeks and 6 weeks after treatment)
  • Average change in results for 2, 4, 6 weeks after treatment as assessed by the clinician-rated Clinical Global Impression-Severity of Illness Scale (CGISI)(At 2 weeks, 4 weeks and 6 weeks after treatment)

研究者

发起方
Ybrain Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验